Kancera AB (publ) commented on the potential for its fractalkine blocking drug candidate KAND567 based on a newly published research publication that summarizes clinical research addressing the pathology driving role of fractalkine axis in cardiovascular disease. KAND567 is currently being studied in the FRACTAL study, an ongoing phase IIa clinical trial in myocardial infarction patients. A newly published research publication in the Journal of Clinical Medicine (J. Clin.

Med. 2023, 12(14), 4821, ?Fractalkine signaling (CX3CL1/CX3CR1 axis) as an emerging target in Coronary Artery Disease?, summarizes the clinical research conducted in the field of the fractalkine axis and its role in cardiovascular disease. Based on the clinical research reviewed, the authors conclude that the fractalkine axis is an attractive future pharmaceutical target for treatment and prevention of life-threatening cardiovascular disease.

Dr. Ioakim Spyridopoulos, one of the authors of the publication, is the primary investigator of the ongoing FRACTAL study, a phase IIa clinical study of Kancera?s fractalkine blocker KAND567 in myocardial infarction patients. The article describes KAND567?s potential as a representative of new class of drugs in the field of cardiovascular disease and the outline of the FRACTAL study. Myocardial infarction is the most serious acute manifestation of cardiovascular disease leading to heart failure, both short and long term.

Despite the advanced treatments available, such as the life-saving percutaneous coronary intervention (PCI), major complications that can be life threatening are common following a myocardial infarction. The clinical research reviewed indicate that the fractalkine axis plays an important role in promoting cardiovascular diseases throughout the disease life cycle, from early changes in the vessels up until a thrombus event that may follow many years later. Accordingly, provided that KAND567 can be used for chronic treatment in the future, KAND567 has the potential to provide patient benefit both in early and late stage cardiovascular disease.